# Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

> **NCT00035178** · PHASE4 · COMPLETED · sponsor: **Texas Biotechnology Corporation** · enrollment: 12 (—)

## Conditions studied

- Kidney Failure, Chronic
- Renal Disease, End-Stage

## Interventions

- **DRUG:** Argatroban

## Key facts

- **NCT ID:** NCT00035178
- **Lead sponsor:** Texas Biotechnology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** 12 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035178, "Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00035178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*